Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
,
Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V, Mansmann U, Wintersperger B, Reiser M, Steinbeck G, et al: Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)rationale, design and first interim analysis
We used Cox regression models, adjusted for potential confounders, to estimate hazard ratios from day 366 after treatment initiation to account for cancer latency
BMJ Open 2021;11:e039358
Although CE-MS is more technically demanding and demonstrates lower sensitivity and higher variability, it is useful for profiling native peptides and secondary metabolites
US$ 20.73
US$ 26.19
US$ 28.18
US$ 26.18
US$ 29.04
US$ 22.07
US$ 21.81
US$ 26.32
US$ 24.25
